Control Risks has appointed Mavis Tan and Simon Blade as senior managing directors in its forensic investigations, compliance and insolvency practice in Hong Kong .

 

These appointments are in response to growing market demand for specialist knowledge in complex cases of fraud, financial disputes and corruption, including FCPA investigations and compliance audits.

 

Between them, Blade and Tan have over 35 years' experience in forensic accounting, litigation support and insolvency. This includes giving expert testimony in a number of criminal and commercial matters involving corruption, fraud, asset-tracing and company valuations. Prior to joining Control Risks, they were both senior managing directors in FTI Consulting's forensic and litigation consulting practice. Joining them will be a multi-skilled team of professionals with extensive experience of assisting multinationals and private clients with pre-transaction due-diligence and post-acquisition compliance issues, shareholder disputes and whistle-blower allegations.

 

The skills and experience of both augment Control Risks' substantial existing forensics and compliance teams in Shanghai , and e-discovery business in Hong Kong . Working with the firm's market-leading crisis management and business intelligence capabilities, this unique combination of skills supports C-suite executives in making critical decisions when faced with complex compliance and investigations issues.

 

Kent Kedl , Control Risks' Managing Director of Greater China and North Asia , said: “Hong Kong is a critical hub for mainland  China and Asia -related investigations, and we are thrilled to have professionals with such depth of experience and credibility in the market to lead our practice there. The challenging regulatory situation in mainland has become more aggressive in the past two years and Mavis, Simon and their team will enable us to help our global clients effectively navigate this increasingly difficult environment.

 

Blade and Tan have been involved in several high profile cases in recent years. These include leading the forensic accounting investigations of the China -based subsidiary of a US-listed medical instrument supplier which led to the client self-reporting to the Securities and Exchange Commission, and conducting an FCPA risk assessment for a US-listed medical devices company after its acquisition, advising in the management of third party distributors in the Greater China region.